Real-world study evaluates contraceptive safety and effectiveness in women

Summaries 1 min 152

Font Size

Created On: 20/06/2026

As women transition through the perimenopausal period, selecting a contraceptive option that balances efficacy with cardiovascular and metabolic safety remains an important clinical consideration.

See All

Key take away

Real-world evidence supports NOMAC-E2 as a safe and effective contraceptive option for perimenopausal women.

Background

As women transition through the perimenopausal period, selecting a contraceptive option that balances efficacy with cardiovascular and metabolic safety remains an important clinical consideration. NOMAC-E2 has emerged as an alternative combined oral contraceptive(COC), but comparative real-world evidence in women remains limited. This real- world study aimed to evaluate the safety and contraceptive effectiveness of NOMAC-E2 compared with levonorgestrel-containing COC (COCLNG) in women aged over 40 years.

Method

A multinational observational cohort study followed women initiating NOMAC-E2 or COCLNG in routine clinical practice across three continents. Prospective questionnaire-based follow-up was used to evaluate thromboembolic safety, contraceptive effectiveness, and treatment-related changes in mood and body weight.

Result

A total of 7,762 women receiving NOMAC-E2 and 6,059 women using COCLNG were included in the analysis.

Key findings included:

Venous thromboembolism (VTE) rates were comparable between the two groups, with no evidence of increased thrombotic risk associated with NOMAC-E2.
Rates of unintended pregnancy remained low and were similar across both contraceptive cohorts.
No clinically meaningful differences were observed in mood-related outcomes.
Body weight changes were comparable between treatment groups.
Overall safety and contraceptive performance of NOMAC-E2 were consistent with those of COCLNG.

Conclusion

The findings indicated that NOMAC-E2 achieved contraceptive efficacy and safety outcomes comparable to those observed with COCLNG in women over 40 years of age. The study supported its use as a reliable contraceptive alternative for perimenopausal women, with no apparent increase in thromboembolic risk or adverse effects on mood and body weight.